Skip to content
DataLookout
Menu

NCT06161025

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 24 versions: 23 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 68 words
    • Trial sites expanded: 164 → 167 locations
    • Secondary endpoints: details revised at 5 of 21 entries
    • Collaborators: details revised at 1 of 1 entry
  2. Minor Trial sites expanded: 152 → 164 locationsv23
  3. Minor Trial sites expanded: 146 → 152 locationsv22
  4. Minor Trial sites expanded: 129 → 146 locationsv21
  5. Minor Trial sites expanded: 120 → 129 locationsv20
Show 17 earlier versionsHide 17 earlier versions
  1. Notable Eligibility criteria shortened, about 374 wordsv19 Show 7 more changesShow less
    • Primary endpoints: 3 to 2
    • Enrollment target: 710 to 860
    • Primary completion date: Dec 31, 2027 to Feb 29, 2028
    • Study completion date: Dec 31, 2029 to Apr 30, 2030
    • Interventions: Gemcitabine (Drug), PLD (Drug), Paclitaxel (Drug), R-DXd (Drug), Topotecan (Drug) to PLD (Drug), Paclitaxel (Drug), R-DXd (Drug), Topotecan (Drug)
    • Secondary endpoints: 16 to 21
    • Site details revised at 47 of 120 sites
  2. Minor Study sites: 116 to 120v18
  3. Minor Study sites: 115 to 116v17
  4. Minor Study sites: 108 to 115v16
  5. Notable Trial status: Active, Not Recruiting to Recruitingv15 Show 5 more changesShow less
    • Eligibility criteria shortened, about 9 words
    • Primary endpoints revised (3)
    • Enrollment target: 650 to 710
    • Study sites: 82 to 108
    • Secondary endpoints revised (16)
  6. Minor Study sites: 81 to 82v13
  7. Minor Study sites: 78 to 81v12
  8. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites revised (78)
    v11
  9. Minor Study sites: 54 to 78v10
  10. Minor Study sites: 40 to 54v9
  11. Minor Study sites: 15 to 40v8
  12. Minor Study sites: 13 to 15v7
  13. Minor Study sites: 3 to 13v6
  14. Minor Study title shortened, about 1 wordv5
  15. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Feb 29, 2024 to Feb 27, 2024
    v4
  16. Notable Eligibility criteria expanded, about 1,081 wordsv3
  17. Minor Secondary endpoints revised (16)v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part A)
Timeframe: From date of randomization to data cut off, up to 18 months
Progression-free Survival (PFS) Based on BICR Assessment (Part B)
Timeframe: From date of randomization to data cut off, up to 26 months

Secondary (21)

Objective Response Rate (ORR) Based on Investigator Assessment
Overall Survival (OS)
Duration of Response (DOR)
Progression-free Survival (PFS) Based on BICR and Investigator Assessment
Disease Control Rate (DCR)
Show 16 moreShow less
Time to Next Treatment (TTNT)
Progression-free Survival 2 (PFS2) Based on Investigator Assessment
Percentage of Participants With Cancer Antigen 125 (CA-125) Response Rate
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Pharmacokinetic (PK) Analysis: Maximum Plasma Drug Concentration (Cmax) of R-DXd
Pharmacokinetic (PK) Analysis: Time to Reach Maximum Plasma Drug Concentration (Tmax) of R-DXP
Pharmacokinetic (PK) Analysis: Area Under the Concentration-Time Curve (AUC) of R-DXd
Percentage of Participants With Treatment Emergent Antidrug Antibody (ADA)
Pharmacokinetic (PK) Analysis: Terminal Half-Life (t1/2) of R-DXd
Change from Baseline in Abdominal/gastrointestinal (GI) Symptoms (Part B)
Change from Baseline in Fatigue/Pain Symptoms (Part B)
Time to Deterioration in Fatigue/Pain Symptoms (Part B)
Time to Deterioration in GI Symptoms (Part B)
Time to Deterioration in Disease Impacts (Part B)
Change from Baseline in Disease Impacts (Part B)
Cadherin-6 (CDH6) protein expression in tumor tissue as determined by immunochemistry assay and correlation with ORR, DoR, PFS and OS

Arms and interventions

Part A: R-DXd 4.8mg/kg Q3WExperimental

Participants will be randomized to receive intravenous R-DXd administered at a dose of 4.8 mg/kg every 3 weeks (Q3W).

Part A: R-DXd 5.6 mg/kg Q3WExperimental

Participants will be randomized to receive intravenous R-DXd administered at a dose of 5.6 mg/kg every 3 weeks (Q3W).

Part A: R-DXd 6.4 mg/kg Q3WExperimental

Participants will be randomized to receive intravenous R-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).

Part B: R-DXd RP3D Q3WExperimental

Participants will be randomized to receive intravenous R-DXd administered at the Recommended Phase 3 Dose (RP3D) every 3 weeks (Q3W).

Part B: Investigator's ChoiceActive comparator

Participants will be randomized to receive intravenous treatment with investigator's choice of paclitaxel, pegylated liposomal doxorubicin (PLD), or topotecan.

Drugs: R-DXd, Paclitaxel, Topotecan, PLD

Sites

167 sites in 19 countries

United States 45, Japan 14, China 13, France 12, Italy 11, Spain 11, South Korea 9, Taiwan 6, Canada 5, Czechia 5, Germany 5, Turkey (Türkiye) 5, United Kingdom 5, Australia 4, Brazil 4, Greece 4, Poland 4, Portugal 4, Finland 1